Searched for: in-biosketch:true
person:katzs04
Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis
Kane, Sunanda; Katz, Seymour; Jamal, M Mazen; Safdi, Michael; Dolin, Ben; Solomon, Dory; Palmen, Mary; Barrett, Karen
BACKGROUND: This was a phase IV, multicenter, open-label, 12-14-month study to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX) mesalamine. A secondary outcome was the relationship between long-term efficacy and adherence. METHODS: Patients with quiescent UC (no rectal bleeding; 0-1 bowel movements more than normal per day) were enrolled directly into a 12-month maintenance phase of the study during which they received MMX mesalamine 2.4 g/day given once daily (QD). Patients with active, mild-to-moderate UC at screening were enrolled into a 2-month acute phase; those who achieved quiescence could continue into the maintenance phase. The primary endpoint was clinical recurrence at Month 6. RESULTS: Of the 290 patients enrolled, 208 entered the maintenance phase; 152 directly and 56 via the acute phase. Following 6 and 12 months of treatment, 76.5% and 64.4% of evaluable patients, respectively, were recurrence-free. The majority of evaluable patients at Month 6 (81.6%) and Month 12 (79.4%) in the maintenance phase were >/= 80% adherent to MMX mesalamine. At Month 6, clinical recurrence was observed in 20.6% of patients who were >/= 80% adherent and 36.1% of patients with <80% adherence (P = 0.05 [post-hoc chi-square analysis]); 31.2% and 52.5% at Month 12 (P = 0.01 [post-hoc chi-square analysis]). CONCLUSIONS: MMX mesalamine 2.4 g/day QD is effective for maintaining quiescence in patients with UC. Furthermore, adherence to prescribed treatment yielded lower rates of clinical recurrence. Continued education regarding the importance of long-term 5-aminosalicylic acid therapy is warranted.
PMID: 21837775
ISSN: 1078-0998
CID: 1446382
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci
Kenny, Eimear E; Pe'er, Itsik; Karban, Amir; Ozelius, Laurie; Mitchell, Adele A; Ng, Sok Meng; Erazo, Monica; Ostrer, Harry; Abraham, Clara; Abreu, Maria T; Atzmon, Gil; Barzilai, Nir; Brant, Steven R; Bressman, Susan; Burns, Edward R; Chowers, Yehuda; Clark, Lorraine N; Darvasi, Ariel; Doheny, Dana; Duerr, Richard H; Eliakim, Rami; Giladi, Nir; Gregersen, Peter K; Hakonarson, Hakon; Jones, Michelle R; Marder, Karen; McGovern, Dermot P B; Mulle, Jennifer; Orr-Urtreger, Avi; Proctor, Deborah D; Pulver, Ann; Rotter, Jerome I; Silverberg, Mark S; Ullman, Thomas; Warren, Stephen T; Waterman, Matti; Zhang, Wei; Bergman, Aviv; Mayer, Lloyd; Katz, Seymour; Desnick, Robert J; Cho, Judy H; Peter, Inga
Crohn's disease (CD) is a complex disorder resulting from the interaction of intestinal microbiota with the host immune system in genetically susceptible individuals. The largest meta-analysis of genome-wide association to date identified 71 CD-susceptibility loci in individuals of European ancestry. An important epidemiological feature of CD is that it is 2-4 times more prevalent among individuals of Ashkenazi Jewish (AJ) descent compared to non-Jewish Europeans (NJ). To explore genetic variation associated with CD in AJs, we conducted a genome-wide association study (GWAS) by combining raw genotype data across 10 AJ cohorts consisting of 907 cases and 2,345 controls in the discovery stage, followed up by a replication study in 971 cases and 2,124 controls. We confirmed genome-wide significant associations of 9 known CD loci in AJs and replicated 3 additional loci with strong signal (p<5x10(-)(6)). Novel signals detected among AJs were mapped to chromosomes 5q21.1 (rs7705924, combined p = 2x10(-)(8); combined odds ratio OR = 1.48), 2p15 (rs6545946, p = 7x10(-)(9); OR = 1.16), 8q21.11 (rs12677663, p = 2x10(-)(8); OR = 1.15), 10q26.3 (rs10734105, p = 3x10(-)(8); OR = 1.27), and 11q12.1 (rs11229030, p = 8x10(-)(9); OR = 1.15), implicating biologically plausible candidate genes, including RPL7, CPAMD8, PRG2, and PRG3. In all, the 16 replicated and newly discovered loci, in addition to the three coding NOD2 variants, accounted for 11.2% of the total genetic variance for CD risk in the AJ population. This study demonstrates the complementary value of genetic studies in the Ashkenazim.
PMCID:3297573
PMID: 22412388
ISSN: 1553-7390
CID: 354142
Long Term Effects of 5-Aminosalicyclic Acid Use on Renal function in the Elderly with Inflammatory Bowel Disease [Meeting Abstract]
Hung, Chun Kit; Gitman, Michael; Feldstein, Richard; Akerman, Meredith; Katz, Seymour
ISI:000208839702457
ISSN: 0002-9270
CID: 4448612
Inflammatory bowel disease of the elderly: frequently asked questions (FAQs)
Katz, Seymour; Pardi, Darrell S
The growing recognition of the older inflammatory bowel disease (IBD) patient is heightened by the entry of the 77.2 million baby boomers who will turn 65 beginning of 2011. It is anticipated that this will occur at a rate of 10,000 per day or 4 million per year for the next 19 years. The management of IBD in this population is complex because of problems with co-morbidities, polypharmacy, impaired mobility, and cognition, as well as difficult social and financial issues. This review focuses on the older IBD patient's unique concerns and provides guidance in their diagnosis and management.
PMID: 21862997
ISSN: 0002-9270
CID: 1446372
Keys to success with clinical trials
Katz, Seymour; Dufficy, Heather; John, Christy
PMCID:3061013
PMID: 21475416
ISSN: 1554-7914
CID: 132223
Screening and diagnosis of prostate cancer in patients with ileal pouch-anal anastomosis: consensus from an expert panel
Shen, Bo; Angermeier, Kenneth W; Remzi, Feza H; Katz, Seymour
Screening for prostate cancer after restorative proctocolectomy with ileal pouch-anal anastomosis can be challenging. Diagnostic biopsy for an elevated level of prostate-specific antigen may present difficulties as well. No guidelines have been issued regarding the value and accuracy of digital examination and the best route to obtain prostate biopsy specimens. A screening and diagnostic algorithm for prostate cancer was developed by an expert consensus panel
PMID: 21301448
ISSN: 1572-0241
CID: 132222
Osteoporosis and gastrointestinal disease
Katz, Seymour; Weinerman, Stuart
Gastrointestinal disease is often overlooked or simply forgotten as a cause of osteoporosis. Yet, the consequences of osteoporotic fractures can be devastating. Although the bulk of the published experience regarding osteoporosis is derived from the postmenopausal population, this review will focus on gastrointestinal disorders implicated in osteoporosis, with an emphasis on inflammatory bowel disease and celiac disease. The unique aspects of gastrointestinal diseases associated with osteoporosis include early onset of disease (and, therefore, prolonged exposure to risk factors for developing osteoporosis, particularly with inflammatory bowel disease and celiac disease), malabsorption, and maldigestion of nutrients necessary for bone health and maintenance (eg, calcium, vitamin D), as well as the impact of glucocorticoids. These factors, when added to smoking, a sedentary lifestyle, hypogonadism, and a family history of osteoporosis, accumulate into an imposing package of predictors for osteoporotic fracture. This paper will review the identification and treatment strategies for patients with gastrointestinal disorders and osteoporosis
PMCID:2950667
PMID: 20978554
ISSN: 1554-7914
CID: 114389
Isolated gastrocnemius myositis related to Crohn's disease
Mogul, Zainab; Katz, Seymour; Bachman, Teresa R; Urmacher, Carlos
PMCID:2933762
PMID: 20827369
ISSN: 1554-7914
CID: 114391
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease
Buchman, Alan L; Katz, Seymour; Fang, John C; Bernstein, Charles N; Abou-Assi, Souheil G
BACKGROUND: Teduglutide, an analog of glucagon-like peptide-2 (GLP-2), is associated with trophic effects on gut mucosa. Its role in the treatment of active Crohn's disease (CD) was assessed in a pilot, randomized, placebo-controlled, double-blinded, dose-ranging study. METHODS: Subjects with moderate-to-severe CD were randomized 1:1:1:1 to placebo or 1 of 3 doses of teduglutide (0.05, 0.10, or 0.20 mg/kg daily) delivered as a daily subcutaneous injection for 8 weeks. The primary outcome measure was the percentage of subjects in each group that responded to treatment, defined as a decrease in Crohn's Disease Activity Index (CDAI) score to <150 or a decrease of > 100 points. At week 8 there was an optional 12-week open-label period of treatment with teduglutide 0.10 mg/kg/d. RESULTS: One hundred subjects were enrolled and 71 completed the study. The mean baseline CDAI score was 290.8 +/- 57.6 and was similar across groups. There were numerically higher response and remission rates in all teduglutide-treated groups as compared with placebo, although the percentage of subjects who achieved a clinical response or remission was more substantial, and seen as early as week 2 of treatment in the highest dose (0.2 mg/kg/d) group (44% response and 32% remission versus 32% response and 20% remission in the placebo group). Of subjects who had not achieved remission during the 8-week placebo-controlled phase in the higher-dose group, 50% achieved remission during the more prolonged, open-label treatment phase. Plasma citrulline was similar across groups at baseline, but increased substantially over time in all teduglutide groups when compared with placebo at week 8. Adverse events were not different between placebo and active treatment groups. CONCLUSIONS: Teduglutide is a novel and potentially effective therapy for inducing remission and mucosal healing in patients with active moderate-to-severe CD. Further clinical investigation of this growth factor is warranted
PMID: 19821509
ISSN: 1536-4844
CID: 114393
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
Reinisch, Walter; de Villiers, Williem; Bene, Laszlo; Simon, Laszlo; Racz, Istvan; Katz, Seymour; Altorjay, Istvan; Feagan, Brian; Riff, Dennis; Bernstein, Charles N; Hommes, Daniel; Rutgeerts, Paul; Cortot, Antoine; Gaspari, Michael; Cheng, May; Pearce, Tillman; Sands, Bruce E
BACKGROUND: The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms. METHODS: A total of 201 patients with Crohn's Disease Activity Index (CDAI) scores between 250 and 450 were randomized to receive an initial intravenous dose of 1.0 or 4.0 mg/kg fontolizumab or placebo, followed by up to 3 subcutaneous doses of 0.1 or 1.0 mg/kg fontolizumab or placebo every 4 weeks. Clinical response at day 29, the primary efficacy endpoint, was defined as a decrease in the CDAI of at least 100 points from baseline levels. RESULTS: Of 201 patients, 135 (67%) completed the study. Day 29 response rates were similar in all treatment groups (31%-38%). At subsequent timepoints a significantly greater proportion of patients in the 1.0 mg/kg intravenous / 1.0 mg/kg subcutaneous fontolizumab group had clinical response and significantly greater improvement in the CDAI score compared with patients who received placebo. All fontolizumab groups had significant improvement in C-reactive protein levels. The overall frequency of adverse events was similar in all groups (58%-75%); most events were related to exacerbation of CD. There was a low frequency (5.2%) of neutralizing antibodies to fontolizumab. CONCLUSIONS: Although a strong clinical response to fontolizumab was not observed, significant decreases in C-reactive protein levels suggest a biological effect. Fontolizumab was well tolerated, and further studies to assess its efficacy are warranted
PMID: 19637334
ISSN: 1536-4844
CID: 114394